Ziwei Luo | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Ziwei Luo | Molecular Mechanisms Signaling | Best Researcher Award

Shenzhen Hospital of Integrated Chinese and Western Medicine | China

Ziwei Luo is an emerging researcher specializing in molecular mechanisms underlying osteoarthritis, stem cell biology, and regenerative medicine. His work focuses on the regulatory roles of microRNAs in cellular differentiation and disease progression, with a particular emphasis on cartilage degeneration and hair follicle stem cell regulation. He has contributed significant findings demonstrating how novel-miR-81 acts as a key modulator in osteoarthritis by targeting IL16, offering new insights into potential therapeutic pathways for degenerative joint diseases. Additionally, his research has elucidated the function of miR-203a-3p in promoting loureirin A–induced differentiation of hair follicle stem cells through Smad1 signaling, expanding understanding of microRNA-mediated control in tissue repair processes. Luo has also identified a regulatory mechanism in which novel-miR-81 enhances chondrocyte differentiation from bone marrow mesenchymal stem cells by suppressing Rac2 expression, highlighting its importance in cartilage regeneration. Collectively, his research advances the field of molecular medicine by uncovering critical microRNA-gene interactions that influence stem cell fate and musculoskeletal tissue remodeling, contributing to the development of innovative therapeutic strategies.

Profile: Orcid

Featured Publications:

1. Luo, Z., Xie, J., Ye, H., Zhang, J., Liu, Y., Ma, C., Cao, J., Pan, H., Liu, X., Zhou, X., et al. (2025). Novel-miR-81 promotes the chondrocytes differentiation of bone marrow mesenchymal stem cells through inhibiting Rac2 expression. CARTILAGE, 16(3), 333–344.

2. Luo, Z., Han, Q., Lu, J., Ouyang, X., Fan, Y., Liu, Y., Zhou, X., Kong, J., Liu, H., Liu, A., et al. (2024). IL16 regulates osteoarthritis progression as a target gene of Novel-miR-81. CARTILAGE.

3. Ye, S., Si, W., Qin, W., Yang, L., Luo, Z., Li, Z., Xie, Y., Pan, H., Li, X., Huang, Z., et al. (2023). Atractylodes lancea volatile oils target ADAR2-miR-181a-5p signaling to mesenchymal stem cell chondrogenic differentiation. The Anatomical Record.

4. Luo, Z., Dou, J., Xie, F., Lu, J., Han, Q., Zhou, X., Kong, J., Chen, D., & Liu, A. (2021). miR-203a-3p promotes loureirin A-induced hair follicle stem cells differentiation by targeting Smad1. The Anatomical Record, 304(3), 531–540.

Abdolraouf Samadi-Maybodi | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Prof. Abdolraouf Samadi-Maybodi | Molecular Mechanisms Signaling | Best Researcher Award

Prof. Abdolraouf Samadi-Maybodi | University of Mazandaran | Iran

Dr. Abdolraouf Samadi-Maybodi is a distinguished Iranian chemist and professor at the University of Mazandaran, Babolsar, Iran. He has played a pivotal role in advancing the field of inorganic and analytical chemistry, particularly through his work in NMR spectroscopy, zeolite synthesis, and nanomaterials. Over a career spanning more than three decades, Dr. Samadi-Maybodi has held various academic positions including Assistant Professor, Associate Professor, and Professor. He has published over 107 research papers in peer-reviewed journals and actively collaborates with international scholars. A member of prestigious societies like the American Chemical Society (ACS), Royal Society of Chemistry (RSC), and Iranian Society of Chemistry, he is recognized for his interdisciplinary contributions that bridge classical chemistry with modern nanotechnology. His leadership roles include serving as Department Head and Research Manager, making him a strong candidate for a Best Researcher Award.

Publication Profile: 

Google Scholar

Education:

Dr. Samadi-Maybodi earned his Ph.D. in Chemistry from the University of Durham, U.K., where he conducted pioneering work on NMR studies of silicate and aluminosilicate solutions under the supervision of Prof. Robin K. Harris. His doctoral thesis, titled “NMR Studies of Silicate and Aluminosilicate Solutions as Precursors for Zeolites,” laid the foundation for much of his later work in zeolite synthesis and spectroscopy. He previously obtained his M.Sc. in Analytical Chemistry  from the University of Mazandaran, Iran, where he explored chemiluminescence of peroxyoxalates under the guidance of Prof. M.R. Hadjmohammadi. His B.Sc. in Chemistry was completed at Shahid Beheshti University, Tehran. This strong academic foundation in both theoretical and applied chemistry has allowed him to integrate classical analytical techniques with modern materials science in his subsequent research.

Experience:

Dr. Samadi-Maybodi has accumulated vast academic experience over nearly four decades. He began his career as a teaching assistant in analytical and instrumental analysis at the University of Mazandaran. He pursued his Ph.D. studies in the UK, followed by a faculty appointment upon his return. His roles at the university include Assistant Professor, Associate Professor, and full Professor from 2008 onwards. He has taught courses across all academic levels, including Advanced NMR Spectroscopy, Thermal Analysis, and Spectroscopic Techniques. His leadership experience includes being Head of the Chemistry Department and Research Manager. He also completed a sabbatical at the University of Western Ontario, Canada. His dedication to teaching, research, and university management demonstrates his holistic contribution to academic science in Iran and abroad.

Research Focus:

Dr. Samadi-Maybodi’s research is deeply rooted in physical and analytical chemistry, with a specialized focus on Nuclear Magnetic Resonance (NMR) spectroscopy for studying silicate and aluminosilicate systems. He is renowned for applying advanced spectroscopic techniques to investigate zeolite formation mechanisms, chemical structures, and solution dynamics. His interest in nanomaterials has led to significant contributions in quantum dots, fluorescence spectroscopy, and photocatalysis. More recently, his work has expanded into environmental chemistry, particularly in the development of novel nanostructured materials for water treatment and pesticide removal. His interdisciplinary approach bridges traditional analytical methods with cutting-edge materials science, resulting in applications across catalysis, environmental cleanup, and energy systems. With over 100 publications, Dr. Samadi-Maybodi continues to make impactful contributions to both fundamental science and applied technologies, maintaining active collaborations with leading researchers worldwide.

Publications Top Notes: 

  1. A new silicate clathrate hydrate: X-ray and NMR study with octameric silicate anions – JSSC

  2. Exchange reactions in aluminosilicate solutions – Chem. Comm.

  3. XRD and NMR study of silicate with nitrogenous cations – Dalton Trans.,

  4. Aluminum incorporation into silicates via 27Al NMR – Zeolites

  5. Discovery of a novel symmetric silicate anion – Dalton Trans.

  6. New oscillating chemiluminescence system with tetraalkylammonium hydroxide – ISBC

  7. Highly resolved 27Al NMR of aluminosilicates – Dalton Trans.

  8. 29Si NMR of methoxysilicic acid in silicate solutions – Mag. Res. Chem.

  9. 29Si DOSY NMR for aqueous silicate studies – Chem. Comm.

  10. Headspace analysis of male/female kiwifruit flowers – J. Essential Oil Res.

Conclusion:

Prof. Abdolraouf Samadi-Maybodi’s research legacy is a testament to decades of scientific dedication, innovation, and academic leadership. His deep-rooted expertise in NMR spectroscopy, silicate chemistry, nanomaterials, and environmental chemistry places him among the leading researchers in his field, especially in Iran and the broader Middle East. His sustained scholarly output, collaborative international engagements, and mentorship of numerous students make him a strong candidate for the Best Researcher Award. With a solid academic foundation, impactful research, and proven administrative skills, Prof. Samadi-Maybodi exemplifies the qualities of a well-rounded and deserving researcher. Recognizing him with this award would not only honor his past contributions but also motivate continued excellence and inspire others in the scientific community.

Kai Zhao | Signal Transduction Mechanisms | Cell Biology Research Award

Published on by Cell Biologist

Dr. Kai Zhao | Signal Transduction Mechanisms | Cell Biology Research Award

Dr. Kai Zhao | shandong first medical university | China

Kai Zhao is a dedicated biomedical scientist specializing in cell biology and translational medical research. Affiliated with the Central Hospital and Shandong First Medical University, Kai has focused on molecular mechanisms underlying diseases such as osteosarcoma and neurodegeneration. Their expertise includes mitophagy regulation, exosomal gene biomarkers, and multi-omics analyses, aiming to discover novel therapeutic targets. Kai has contributed significantly to understanding how cellular degradation pathways influence disease progression, with published work in prominent journals. They hold key roles in both clinical and research settings, bridging basic science and patient care. Their collaborative work and innovative approach have garnered attention in the biomedical community, underscoring their role as a rising leader in cell biology research.

Publication Profile: 

Orcid

Education:

Kai Zhao completed their foundational studies in medicine at a prestigious medical university in China, followed by advanced graduate training focusing on cellular and molecular biology. Their education provided a strong grounding in clinical medicine combined with rigorous laboratory research skills. They further specialized through postgraduate work that integrated molecular biology techniques and omics technologies, developing expertise in the mechanisms of disease at a cellular level. This multidisciplinary education enabled Kai to pursue research at the interface of clinical practice and experimental biology. They have also completed specialized training in bone biomechanics and metabolism, as well as spinal surgery, enhancing their ability to conduct translational research. Continuous professional development through workshops, conferences, and collaborative projects complements their formal education, keeping them updated on cutting-edge scientific advances.

Experience:

Kai Zhao has extensive experience working at the Central Hospital Affiliated with Shandong First Medical University, where they contribute both clinically and in research. Their experience includes investigating molecular pathways in osteosarcoma and neurodegenerative models using cell lines such as SH-SY5Y. Kai has led projects applying multi-omics data to identify exosomal gene biomarkers and therapeutic targets like mifepristone. Their role in the Spinal Surgery Department and Bone Biomechanics Laboratory has provided hands-on clinical insight, informing their research on bone and spinal disorders. Kai collaborates with multidisciplinary teams, combining clinical knowledge with molecular techniques. Their publication record reflects proficiency in advanced methodologies such as mitophagy analysis, molecular degradation pathways, and biomarker discovery. Kai also mentors junior researchers and participates in academic dissemination through publications and conferences, demonstrating leadership and a commitment to advancing cell biology research.

Research Focus:

Kai Zhao’s research centers on the molecular and cellular mechanisms driving disease, with an emphasis on mitophagy, exosomal biomarkers, and multi-omics analyses. They investigate how cellular quality control systems, such as the PINK1-mediated mitophagy pathway, contribute to neurodegenerative diseases and cancer progression, specifically osteosarcoma. By combining genomic, proteomic, and transcriptomic data, Kai aims to identify novel gene biomarkers within exosomes that can serve as diagnostic or therapeutic targets. One highlighted therapeutic candidate from their work is mifepristone, revealed through integrative multi-omics to be effective against osteosarcoma. Their research integrates cellular biology with clinical insights, particularly in bone metabolism and spinal diseases, aiming for translational impact. Overall, Kai’s focus is on uncovering how disruptions in cellular degradation and intercellular communication contribute to disease, leveraging multi-disciplinary approaches to develop targeted therapies.

Publication Top Notes:

    • Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi‐Omics Analysis

    • IRGM promotes the PINK1-mediated mitophagy through the degradation of Mitofilin in SH-SY5Y cells

Conclusion:

Kai Zhao is a promising and capable researcher whose work directly contributes to cutting-edge cell biology, particularly in disease mechanisms. Their multi-omics and cellular degradation studies mark them as an excellent candidate for the Cell Biology Research Award.

Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Published on by Cell Biologist

Ms. Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Ms. Xiaoyan Wang | Fudan University | China

Dr. Xiaoyan Wang is a dedicated cardiologist and postdoctoral fellow at Fudan University with a strong background in both clinical practice and cardiovascular research. With over a decade of academic training and medical experience, she has built expertise in ventricular remodeling, percutaneous coronary interventions, and immune responses in heart diseases. Under the mentorship of esteemed scholars such as Dr. Yunzeng Zou and Academician Yaling Han, she has published extensively in high-impact journals, reflecting her commitment to scientific advancement. Dr. Wang is currently a scholar in Harvard Medical School’s Global Clinical Scholars Research Training program and also serves as a section editor for the AME Clinical Trials Review. She actively contributes to academic communities, notably by organizing the “Excellent Academic Research Communication Club.” Her work bridges translational medicine and clinical application, aiming to improve cardiovascular patient outcomes through innovative, evidence-based approaches.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Academic Credentials: Dr. Wang has earned her PhD from the prestigious Fudan University and is currently in the Harvard Medical School’s Global Clinical Scholars Research Training Program, signaling a top-tier academic and global research profile.

  2. Dual Research Strength in Basic and Clinical Sciences: She demonstrates an exceptional ability to bridge molecular mechanisms (e.g., immune pathways, cGAS-STING, miRNAs, circular RNAs) with clinical relevance (e.g., myocardial infarction prognosis, anemia impact in PCI), making her work highly translational.

  3. High-Impact Publications: First-author or co-first-author in peer-reviewed journals such as Signal Transduction and Targeted Therapy, Angiology, and Frontiers in Cardiovascular Medicine, with publications tackling cutting-edge cardiovascular topics.

  4. Collaborative and Interdisciplinary Focus: Contributions across institutions and disciplines—partnering with bioinformaticians, clinicians, and molecular scientists—demonstrate strong collaboration skills.

  5. Recognition & Editorial Role: Multiple awards (CPSF Fellowship, Super Postdoc at Fudan) and an editorial position at AME Clinical Trials Review show leadership and peer acknowledgment.

🛠️ Areas for Improvement:

  1. More First-Author Lead on Recent Papers: Although she holds strong co-first authorships and collaborative contributions, maintaining or increasing sole first-author outputs on impactful papers would further strengthen individual scholarly identity.

  2. Increased International Conference Visibility: While she has presented at JCS, continued or expanded visibility in global cardiovascular congresses (e.g., AHA, ESC, ACC) would enhance recognition.

  3. Grant Leadership: Future grant applications as a principal investigator (rather than team member) could affirm her leadership in project design and execution.

🎓 Education :

Dr. Xiaoyan Wang holds a Ph.D. from Fudan University’s Zhongshan Hospital (2016–2019), where she conducted fundamental research on ventricular remodeling under Dr. Yunzeng Zou’s mentorship, supported by prestigious national fellowships. She earned her Master’s degree from Dalian Medical University (2013–2016), focusing on clinical research in percutaneous coronary intervention, under Academician Yaling Han. Her academic foundation was laid with a Bachelor’s degree in Medicine from Fujian Medical University (2007–2012). Currently, she is advancing her research and clinical skills in the prestigious Global Clinical Scholars Research Training Program at Harvard Medical School (2024–2025), blending in-person and online modules. Her multi-tiered education reflects a deep integration of basic science, translational medicine, and clinical practice in cardiovascular health, equipping her to lead high-impact research and patient care initiatives.

💼 Experience:

Dr. Wang is currently a Postdoctoral Fellow at Fudan University (since 09/2023), working under Prof. Yunzeng Zou. She is also the organizer of the Excellent Academic Research Communication Club, promoting interdisciplinary dialogue. From 07/2022 to 07/2023, she served as a cardiologist at Shanghai Jiaotong University’s Ruijin Hospital, and from 2019 to 2022, as a resident in internal medicine at Zhongshan Hospital. In 2024, she began contributing as a section editor for AME Clinical Trials Review, enhancing the quality and visibility of clinical trial research. Her experience spans clinical cardiology, postdoctoral research, editorial responsibilities, and academic leadership. These roles have solidified her ability to translate scientific knowledge into medical practice, particularly in the cardiovascular field.

🏆 Awards & Honors:

Dr. Wang has received numerous accolades recognizing her academic excellence and research impact. In 2023, she was awarded both the Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation (CPSF) and the prestigious Super Postdoctoral Fellowship of Fudan University, underscoring her leadership in postdoctoral research. Her communication and writing skills were acknowledged with the Third Prize in the 8th “Buchang Cup” Young Physician Essay Contest (2019). She also presented Late Breaking Cohort Studies at the Japanese Circulation Society (JCS) Annual Meeting 2019, reflecting international recognition of her scientific contributions. These honors reflect her potential as a rising leader in cardiovascular medicine and support her suitability for the Best Paper Award.

🔬 Research Focus :

Dr. Wang’s research focuses on cardiovascular disease mechanisms, particularly immune system regulation, ventricular remodeling, and the molecular basis of heart failure. Her Ph.D. and postdoctoral studies have addressed the cGAS-STING pathway, miRNA biomarkers, circular RNAs, and inflammation-related signaling in cardiovascular dysfunction. She has also explored clinical prognostic models, such as CHA2DS2-VASc scoring, and interventions including left atrial appendage occlusion and shock wave therapy for ischemic cardiomyopathy. Her dual interest in basic science and clinical outcomes allows her to design translational research that bridges laboratory findings and therapeutic advancements. With a strong publication record and ongoing involvement in global research training at Harvard Medical School, her work aims to inform precision medicine strategies in cardiology.

📚 Publication Titles Top Notes:

  1. 🧠 The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications

  2. 🔗 The connection of immune response and cGAS-STING pathway in cardiovascular disease

  3. 🐭 Left ventricular response in hypertrophy-to-failure transition: roles of Akt, β-arrestin-2, and CaMKII

  4. 💉 Circulating miRNAs in hypertension: diagnostic value and bioinformatics analysis

  5. 🧪 Galectin-3 inhibition improves endothelial progenitor function via autophagy suppression

  6. 🔄 Circular RNA in cardiovascular disease

📌 Conclusion:

Dr. Xiaoyan Wang is highly suitable for the Research for Best Paper Award. Her profile reflects a rare and valuable integration of basic cardiovascular science and clinical innovation, with high-impact, well-cited publications and ongoing international training. Her trajectory, marked by excellence, discipline, and collaborative leadership, meets and exceeds the criteria for this award.